Merkel cell carcinoma: Mitoses, expression of Ki-67 and bcl-2 correlate with disease progression

Journal of the European Academy of Dermatology and Venereology

Volumn 29, Issue 3, 2015, Pages 542-548

  Vujic, I ^a   Marker, M ^b   Posch, C ^a   Muhlehner D ^b   Monshi, B ^b   Breier, F ^c   Steiner, A ^c   Ortiz Urda, S ^a   Rappersberger, K ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b KRANKENANSTALT RUDOLFSTIFTUNG   (Austria)

^c Neurological Center Rosenhuegel   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

KI 67 ANTIGEN; MONOCLONAL ANTIBODY D2-40; PARAFFIN; PODOPLANIN; PROTEIN BCL 2; PROTEIN P53; PROTEIN P63;

ADULT; AGED; APOPTOSIS; ARTICLE; CANCER RECURRENCE; CELL INFILTRATION; CELL INVASION; CELL PROLIFERATION; CELL SURVIVAL; CLINICAL ARTICLE; CLINICAL ASSESSMENT; DISEASE ASSOCIATION; DISEASE COURSE; DISTANT METASTASIS; FEMALE; FOLLOW UP; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; LYMPH VESSEL; MALE; MERKEL CELL TUMOR; MITOSIS INDEX; OUTCOME ASSESSMENT; PRIMARY TUMOR; PRIORITY JOURNAL; RECURRENT DISEASE; SINGLE BLIND PROCEDURE; STAINING; TUMOR CELL; TUMOR GROWTH; TUMOR VOLUME; IMMUNOLOGY; METABOLISM; MIDDLE AGED; MITOSIS; PATHOLOGY; SKIN TUMOR; VERY ELDERLY;

AGED; AGED, 80 AND OVER; CARCINOMA, MERKEL CELL; DISEASE PROGRESSION; FEMALE; HUMANS; KI-67 ANTIGEN; MALE; MIDDLE AGED; MITOSIS; PROTO-ONCOGENE PROTEINS C-BCL-2; SKIN NEOPLASMS;

EID: 84923091444     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/jdv.12626     Document Type: Article

References (49)

1. Toker C,. Trabecular carcinoma of the skin. Arch Dermatol 1972; 105: 107-110.
2. Tang CK, Toker C,. Trabecular carcinoma of the skin: an ultrastructural study. Cancer 1978; 42: 2311-2321.
3. Toker C,. Trabecular carcinoma of the skin. A question of title. Am J Dermatopathol 1982; 4: 497-500.
4. Albores-Saavedra J, Batich K, Chable-Montero F, Sagy N, Schwartz AM, Henson DE,. Merkel cell carcinoma demographics, morphology, and survival based on 3870 cases: a population based study. J Cutan Pathol 2010; 37: 20-27.
5. Becker J, Mauch C, Kortmann R-D, et al,. Short German guidelines: Merkel cell carcinoma. J Dtsch Dermatol Ges 2008; 6 (Suppl. 1): S15-S16.
6. Liao PB,. Merkel cell carcinoma. Dermatol Ther 2008; 21: 447-451.
7. Hodgson NC,. Merkel cell carcinoma: changing incidence trends. J Surg Oncol 2005; 89: 1-4.
8. Koljonen V,. Merkel cell carcinoma. World J Surg Oncol 2006; 4: 7.
9. Llombart B, Monteagudo C, Lõpez-Guerrero JA, et al,. Clinicopathological and immunohistochemical analysis of 20 cases of Merkel cell carcinoma in search of prognostic markers. Histopathology 2005; 46: 622-634.
10. Asioli S, Righi A, Volante M, Eusebi V, Bussolati G,. p63 expression as a new prognostic marker in Merkel cell carcinoma. Cancer 2007; 110: 640-647.
11. Tucci MG, Lucarini G, Giangiacomi M, et al,. Immunohistochemical study of apoptosis markers and involvement of chemokine CXCR4 in skin Merkel cell carcinoma. J Eur Acad Dermatol Venereol JEADV 2006; 20: 1220-1225.
12. Andea AA, Coit DG, Amin B, Busam KJ,. Merkel cell carcinoma: histologic features and prognosis. Cancer 2008; 113: 2549-2558.
13. Skelton HG, Smith KJ, Hitchcock CL, McCarthy WF, Lupton GP, Graham JH,. Merkel cell carcinoma: analysis of clinical, histologic, and immunohistologic features of 132 cases with relation to survival. J Am Acad Dermatol 1997; 37: 734-739.
14. Ng L, Beer TW, Murray K,. Vascular density has prognostic value in Merkel cell carcinoma. Am J Dermatopathol 2008; 30: 442-445.
15. Sandel HD, 4th, Day T, Richardson MS, Scarlett M, Gutman KA,. Merkel cell carcinoma: does tumor size or depth of invasion correlate with recurrence, metastasis, or patient survival? Laryngoscope 2006; 116: 791-795.
16. Becker JC, Kauczok CS, Ugurel S, Eib S, Bröcker EB, Houben R,. Merkel cell carcinoma: molecular pathogenesis, clinical features and therapy. J Dtsch Dermatol Ges 2008; 6: 709-719.
17. Lim CS, Whalley D, Haydu LE, et al,. Increasing tumor thickness is associated with recurrence and poorer survival in patients with Merkel cell carcinoma. Ann Surg Oncol 2012; 19: 3325-3334.
18. Niakosari F, Kahn HJ, McCready D, et al,. Lymphatic invasion identified by monoclonal antibody D2-40, younger age, and ulceration: predictors of sentinel lymph node involvement in primary cutaneous melanoma. Arch Dermatol 2008; 144: 462-467.
19. Doeden K, Ma Z, Narasimhan B, Swetter SM, Detmar M, Dadras SS,. Lymphatic invasion in cutaneous melanoma is associated with sentinel lymph node metastasis. J Cutan Pathol 2009; 36: 772-780.
20. Fohn LE, Rodriguez A, Kelley MC, et al,. D2-40 lymphatic marker for detecting lymphatic invasion in thin to intermediate thickness melanomas: association with sentinel lymph node status and prognostic value-a retrospective case study. J Am Acad Dermatol 2011; 64: 336-345.
21. Yamada Y, Matsumoto T, Arakawa A, et al,. Evaluation using a combination of lymphatic invasion on D2-40 immunostain and depth of dermal invasion is a strong predictor for nodal metastasis in extramammary Paget's disease. Pathol Int 2008; 58: 114-117.
22. Walgenbach-Bruenagel G, Tolba RH, Varnai AD, Bollmann M, Hirner A, Walgenbach KJ,. Detection of lymphatic invasion in early stage primary colorectal cancer with the monoclonal antibody D2-40. Eur Surg Res 2006; 38: 438-444.
23. Mori D, Yamasaki F, Shibaki M, Tokunaga O,. Lateral peritumoral lymphatic vessel invasion can predict lymph node metastasis in esophageal squamous cell carcinoma. Mod Pathol 2007; 20: 694-700.
24. Marinho VFZ, Metze K, Sanches FSF, Rocha GFS, Gobbi H,. Lymph vascular invasion in invasive mammary carcinomas identified by the endothelial lymphatic marker D2-40 is associated with other indicators of poor prognosis. BMC Cancer 2008; 8: 64.
25. Kahn HJ, Bailey D, Marks A,. Monoclonal antibody D2-40, a new marker of lymphatic endothelium, reacts with Kaposi's sarcoma and a subset of angiosarcomas. Mod Pathol 2002; 15: 434-440.
26. Mott RT, Smoller BR, Morgan MB,. Merkel cell carcinoma: a clinicopathologic study with prognostic implications. J Cutan Pathol 2004; 31: 217-223.
27. Fields RC, Busam KJ, Chou JF, et al,. Five hundred patients with Merkel cell carcinoma evaluated at a single institution. Ann Surg 2011; 254: 465-473; discussion 473-475.
28. Gupta SG, Wang LC, Peñas PF, Gellenthin M, Lee SJ, Nghiem P,. Sentinel lymph node biopsy for evaluation and treatment of patients with Merkel cell carcinoma: the Dana-Farber experience and meta-analysis of the literature. Arch Dermatol 2006; 142: 685-690.
29. Breslow A,. Thickness, cross-sectional areas and depth of invasion in the prognosis of cutaneous melanoma. Ann Surg 1970; 172: 902-908.
30. Medina-Franco H, Urist MM, Fiveash J, Heslin MJ, Bland KI, Beenken SW,. Multimodality treatment of Merkel cell carcinoma: case series and literature review of 1024 cases. Ann Surg Oncol 2001; 8: 204-208.
31. Rindi G, Klöppel G, Alhman H, et al,. TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Arch 2006; 449: 395-401.
32. Rindi G, Klöppel G, Couvelard A, et al,. TNM staging of midgut and hindgut (neuro) endocrine tumors: a consensus proposal including a grading system. Virchows Arch 2007; 451: 757-762.
33. McCall CM, Shi C, Cornish TC, et al,. Grading of well-differentiated pancreatic neuroendocrine tumors is improved by the inclusion of both Ki67 proliferative index and mitotic rate. Am J Surg Pathol 2013; 37: 1671-1677.
34. Lipponen PK, Eskelinen MJ, Collan Y, Marin S, Alhava E,. Volume-corrected mitotic index in human pancreatic cancer. Relation to histologic grade, clinical stage, and prognosis. Scand J Gastroenterol 1990; 25: 548-554.
35. Strosberg J, Nasir A, Coppola D, Wick M, Kvols L,. Correlation between grade and prognosis in metastatic gastroenteropancreatic neuroendocrine tumors. Hum Pathol 2009; 40: 1262-1268.
36. Koljonen V, Tukiainen E, Haglund C, Böhling T,. Proliferative activity detected by Ki67 correlates with poor outcome in Merkel cell carcinoma. Histopathology 2006; 49: 551-553.
37. Fernández-Figueras M-T, Puig L, Eva Musulen, et al,. Expression profiles associated with aggressive behavior in Merkel cell carcinoma. Mod Pathol 2007; 20: 90-101.
38. Moll I, Gillardon F, Waltering S, Schmelz M, Moll R,. Differences of bcl-2 protein expression between Merkel cells and Merkel cell carcinomas. J Cutan Pathol 1996; 23: 109-117.
39. Sahi H, Koljonen V, Kavola H, et al,. Bcl-2 expression indicates better prognosis of Merkel cell carcinoma regardless of the presence of Merkel cell polyomavirus. Virchows Arch 2012; 461: 553-559.
40. Knapp CF, Sayegh Z, Schell MJ, et al,. Expression of CXCR4, E-Cadherin, Bcl-2, and Survivin in Merkel Cell Carcinoma: an Immunohistochemical Study Using a Tissue Microarray. J Dermatopathol 2012; 34: 592-596.
41. Feinmesser M, Halpern M, Fenig E, et al,. Expression of the apoptosis-related oncogenes bcl-2, bax, and p53 in Merkel cell carcinoma: can they predict treatment response and clinical outcome? Hum Pathol 1999; 30: 1367-1372.
42. Kukko HM, Koljonen VSK, Tukiainen EJ, Haglund CH, Böhling TO,. Vascular invasion is an early event in pathogenesis of Merkel cell carcinoma. Mod Pathol 2010; 23: 1151-1156.
43. Yang A, Kaghad M, Wang Y, et al,. p63, a p53 homolog at 3q27-29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities. Mol Cell 1998; 2: 305-316.
44. Di Como CJ, Urist MJ, Babayan I, et al,. p63 expression profiles in human normal and tumor tissues. Clin Cancer Res 2002; 8: 494-501.
45. Lo Muzio L, Santarelli A, Caltabiano R, et al,. p63 overexpression associates with poor prognosis in head and neck squamous cell carcinoma. Hum Pathol 2005; 36: 187-194.
46. Takeuchi Y, Tamura A, Kamiya M, Fukuda T, Ishikawa O,. Immunohistochemical analyses of p63 expression in cutaneous tumours. Br J Dermatol 2005; 153: 1230-1232.
47. Hall BJ, Pincus LB, Yu SS, Oh DH, Wilson AR, McCalmont TH,. Immunohistochemical prognostication of Merkel cell carcinoma: p63 expression but not polyomavirus status correlates with outcome. J Cutan Pathol 2012; 39: 911-917.
48. Asioli S, Righi A, de Biase D, et al,. Expression of p63 is the sole independent marker of aggressiveness in localised (stage I-II) Merkel cell carcinomas. Mod Pathol 2011; 24: 1451-1461.
49. Werchau S, Toberer F, Enk A, Dammann R, Helmbold P,. Merkel cell carcinoma induces lymphatic microvessel formation. J Am Acad Dermatol 2012; 67: 215-225.